These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17030701)

  • 1. The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?
    Blankenberg S; Yusuf S
    Circulation; 2006 Oct; 114(15):1557-60. PubMed ID: 17030701
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [C-reactive protein: cardiovascular issues of an acute-phase protein].
    Amezcua-Guerra LM; Springall del Villar R; Bojalil Parra R
    Arch Cardiol Mex; 2007; 77(1):58-66. PubMed ID: 17500194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group.
    Smith SC; Anderson JL; Cannon RO; Fadl YY; Koenig W; Libby P; Lipshultz SE; Mensah GA; Ridker PM; Rosenson R; ;
    Circulation; 2004 Dec; 110(25):e550-3. PubMed ID: 15611380
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk assessment in the patient with established peripheral arterial disease.
    Haugen S; Casserly IP; Regensteiner JG; Hiatt WR
    Vasc Med; 2007 Nov; 12(4):343-50. PubMed ID: 18048472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
    Guijarro C
    Circulation; 2001 Nov; 104(22):E127. PubMed ID: 11723039
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter by Ridker and Everett regarding article, "The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?".
    Ridker PM; Everett BM
    Circulation; 2007 May; 115(20):e475; author reply e476. PubMed ID: 17515471
    [No Abstract]   [Full Text] [Related]  

  • 8. Early life origins of low-grade inflammation and atherosclerosis risk in children and adolescents.
    Labayen I; Ortega FB; Sjöström M; Ruiz JR
    J Pediatr; 2009 Nov; 155(5):673-7. PubMed ID: 19595364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRP has little incremental value over traditional cardiovascular risk factors in risk stratification.
    Farkouh ME; Bansilal S; Mathew V
    Nat Clin Pract Cardiovasc Med; 2007 Jun; 4(6):290-1. PubMed ID: 17522718
    [No Abstract]   [Full Text] [Related]  

  • 10. C-reactive protein in cardiovascular risk prediction. Zooming in and zooming out.
    Maseri A
    Ital Heart J; 2001 Mar; 2(3):155-6. PubMed ID: 11305525
    [No Abstract]   [Full Text] [Related]  

  • 11. C-reactive protein testing comes of age. Measuring low-grade inflammation can help refine cardiovascular risk.
    Harv Heart Lett; 2009 Feb; 19(6):2. PubMed ID: 19575518
    [No Abstract]   [Full Text] [Related]  

  • 12. High-Sensitivity C-Reactive Protein and Statin Initiation.
    Trpkovic A; Stanimirovic J; Rizzo M; Resanovic I; Soskic S; Jevremovic D; Isenovic ER
    Angiology; 2015 Jul; 66(6):503-7. PubMed ID: 25053677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
    Corson MA; Jones PH; Davidson MH
    Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reverse epidemiology reflects C-reactive protein as a bystander of atherosclerosis in established systemic inflammation models.
    Lin GM; Chu KM; Han CL
    Int J Cardiol; 2011 Feb; 146(3):422-3. PubMed ID: 21093078
    [No Abstract]   [Full Text] [Related]  

  • 16. Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis?
    Paraskevas KI; Bessias N; Papas TT; Andrikopoulos V; Mikhailidis DP
    Angiology; 2009; 60(1):8-11. PubMed ID: 19190029
    [No Abstract]   [Full Text] [Related]  

  • 17. [C-reactive protein in cardiovascular diseases].
    Lubas W; Gutkowski K
    Przegl Lek; 2006; 63(7):562-6. PubMed ID: 17203810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The revival of an old diagnostic marker: C-reactive protein].
    Sela B
    Harefuah; 2001 Jun; 140(6):541-6. PubMed ID: 11420859
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic inflammation. For some, a cardiovascular risk.
    Mayo Clin Health Lett; 2008 Jul; 26(7):4-5. PubMed ID: 18693337
    [No Abstract]   [Full Text] [Related]  

  • 20. A better way to predict cardiovascular risk. We know how important cholesterol levels are, but what about inflammation?
    Harv Womens Health Watch; 2007 Apr; 14(8):1-2. PubMed ID: 17441261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.